Top

Published in:

01-11-2011 | Clinical Study - Patient Study

Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma

Authors: Gianluca Marucci, Luca Morandi

Published in: Journal of Neuro-Oncology | Issue 2/2011

Abstract

Although pleomorphic xanthoastrocytoma (PXA) is currently designed as a grade II glioma according to the WHO classification, a significant percentage of the tumors undergo malignant progression. In this study, the MGMT methylation status was examined in 11 PXA patients to determine if a biologic rationale exists to support the use of temozolomide (TMZ) for treatment of aggressive PXA. There were 9 cases of PXA grade II and 2 cases of PXA with anaplastic features. In the MGMT methylation study, only 2 (18.1%) of the 11 tumor samples tested by MS-qLNAPCR were positive for MGMT promoter methylation. In contrast, other cases, including PXAs with anaplastic features, were unmethylated. In addition, a tumor recurrence was found to be unmethylated. Thus, MGMT promoter methylation is not frequent in PXA and our results raise doubts about the benefits of treating indistinctly aggressive PXA with TMZ.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) World Health Organization classification of tumours of the central nervous system. IARC Press, Lyon

Giannini C, Scheithauer BW, Burger PC et al (1999) Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer 85:2033–2045PubMed

Pahapill PA, Ramsay DA, Del Maestro RF (1996) Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. Neurosurgery 38:822–828PubMedCrossRef

Alexiou GA, Moschovi M, Stefanaki K, Prodromou C, Sfakianos G, Prodromou N (2010) Malignant progression of a pleomorphic xanthoastrocytoma in a child. Neuropediatrics 41:69–71PubMedCrossRef

Tsutsumi S, Abe Y, Yasumoto Y, Ito M (2010) Anaplastic pleomorphic xanthoastrocytoma with a component of anaplastic astrocytoma presenting as skull base tumor followed by downward extracranial extension. Neurol Med Chir 50:1108–1112CrossRef

Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRef

Morandi L, Franceschi E, de Biase D et al (2010) Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. BMC Cancer 10:48PubMedCrossRef

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCt method. Methods 25:402–408PubMedCrossRef

Houillier C, Wang X, Kaloshi G et al (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560–1566PubMedCrossRef

Title: Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma
Authors: Gianluca Marucci
Luca Morandi
Publication date: 01-11-2011
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2011
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-011-0605-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Primary intraocular lymphoma: a review

Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma

The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma

Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma

Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity

Possible association between genetic variants in the H2AFX promoter region and risk of adult glioma in a Chinese Han population